Palabras clave
Síndrome antifosfolipídico
Anticuerpos antifosfolipídicos
Anticuerpos anticardiolipina
Anticoagulante lúpico
Anticuerpos antifosfolipídicos
Anticuerpos anticardiolipina
Anticoagulante lúpico
Cómo citar
Cervera, R. (2020). Síndrome antifosfolipídico catastrófico: síndrome de Asherson. Médicas UIS, 21(3), 183–191. Recuperado a partir de https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/12319
Resumen
Aunque representan menos del 1% de todos los pacientes con síndrome antifosfolipídico, los pacientes con síndrome antifosfolipídico catastrófi co generalmente se encuentran en una situación médica urgente que requiere un seguimiento clínico exhaustivo. Sin embargo, la rareza de esta variante difi culta extraordinariamente
su estudio sistemático. Con la fi nalidad de incluir todos los casos publicados con síndrome antifosfolipídico catastrófi co, así como los nuevos casos que se van diagnosticando en todo el mundo, se creó en el año 2000 un registro internacional (“CAPS Registry”), promovido por el European Forum on Antiphospholipid Antibodies.Actualmente, este registro documenta las manifestaciones clínicas y los datos de laboratorio y terapéuticos de más de 300 pacientes. Se puede consultar libremente en Internet (www.med.ub.es/MIMMUN/FORUM/CAPS.HTM) y se espera que el análisis periódico de sus datos permita incrementar los conocimientos sobre el
síndrome antifosfolipídico catastrófi co. En este artículo se revisan los principales conocimientos obtenidos hasta la fecha sobre este síndrome. (MÉD. UIS. 2008;21(3):183-91).
Referencias
1. Asherson RA. The catastrophic antiphospholipid antibody syndrome. J Rheumatol. 1992;19:508-12.
2. Piette JC, Cervera R, Levy R, Nasonov EL, Triplett DA, Shoenfeld Y. The catastrophic antiphospholipid syndrome – Asherson’s syndrome. Ann Med Intern. 2003;154:95-6.
3. Greisman SG, Thayaparan R-S, Godwin TA, Lockshin MD. Occlusive vasculopathy in systemic lupus erythematosus - Association with anticardiolipin antibody. Arch Intern Med.
1991;151:389-92.
4. Harris EN, Bos K. An acute disseminated coagulopathyvasculopathy associated with the antiphopholipid syndrome. Arch Intern Med. 1991;151:231-2.
5. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Borcoglu A, et al. Catastrophic antibody syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore).
1998;77:195-207.
6. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G,Petri MA, et al. Catastrophic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80:355-76.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
8. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. The long-term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530-3.
9. Asherson RA, Cervera R, de Groot P, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-4.
10. Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-9.
11. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - Molecular mimicry? J Rheumatol. 2000;27:12-4.
12. Gharavi E, Cucurull E, Tang H, Celli CM, Wilson WA, Gharavi AE. Induction of antiphospholipid antibodies by immunization with viral peptides. Lupus 1999; 8: 449-455.
13. Gharavi AE, Pierangeli SS, Harris N. New developments in viral peptides and antiphospholipid antibody induction. J Autoimmunity. 2000;15:227-30.
14. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2006;65:2-6.
15. Gómez-Puerta JA, Cervera R, Espinosa G, Aguiló S, Bucciarelli S, Ramos-Casals M, et al. Antiphospholipid antibodies associated with malignancies: Clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35:322-32.
16. Kitchens CS. Thrombotic storm: When thrombosis begets thrombosis. Am J Med. 1998;104:381-5.
17. Amital H, Levy Y, Davidson C, Lundberg I, Harju A, Kosach Y, et al. Catastrophic antiphospholipid syndrome: remission following leg amputation. Semin Arthritis Rheum. 2001;31:127-132.
18. Cervera R, Bucciarelli S, Espinosa G, Gómez-Puerta JA, Ramos-Casals M, Shoenfeld Y, Piette J-C, Asherson RA. Catastrophic antiphospholipid syndrome: Lessons from the CAPS Registry” A tribute to the late Josep Font. Ann NY Acad Sci. 2007;1108:448-56.
19. Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: Therapeutic developments. Expert Rev Clin Immunol. 2007;3:277-85 20. Espinosa G, Bucciarelli S, Cervera R,
ómez-Puerta JA, Font J. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:68-71.
21. Cervera R, Asherson RA, Font J. Catastrophic antiphospholipid syndrome. Rheum Dis Clin N Am. 2006;32: 575-90.
22. Bucciarelli S, Espinosa G, Asherson RA, Cervera R, Claver G, Gómez-Puerta JA, et al. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis
f a series of 47 patients. Ann Rheum Dis. 2006;65: 81-6.
23. Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome:
linical and haematological characteristics of 23 patients. Ann Rheum Dis. 2005;64:943-6.
24. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, De la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum is. 2004;63:730-6.
25. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification
riteria for definite antiphospholipid syndrome (APS). J Thromb Haemostas. 2006;4:295-306.
26. Bucciarelli S, Espinosa G, Cervera R, Erkan D, GómezPuerta JA, Ramos-Casals M, et al. For the CAPS Registry Project Group (European Forum on Antiphsopholipid Antibodies).
ortality in the catastrophic antiphospholipid syndrome. Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568-76.
2. Piette JC, Cervera R, Levy R, Nasonov EL, Triplett DA, Shoenfeld Y. The catastrophic antiphospholipid syndrome – Asherson’s syndrome. Ann Med Intern. 2003;154:95-6.
3. Greisman SG, Thayaparan R-S, Godwin TA, Lockshin MD. Occlusive vasculopathy in systemic lupus erythematosus - Association with anticardiolipin antibody. Arch Intern Med.
1991;151:389-92.
4. Harris EN, Bos K. An acute disseminated coagulopathyvasculopathy associated with the antiphopholipid syndrome. Arch Intern Med. 1991;151:231-2.
5. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Borcoglu A, et al. Catastrophic antibody syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore).
1998;77:195-207.
6. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G,Petri MA, et al. Catastrophic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore). 2001;80:355-76.
7. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019-27.
8. Erkan D, Asherson RA, Espinosa G, Cervera R, Font J, Piette JC, et al. The long-term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530-3.
9. Asherson RA, Cervera R, de Groot P, Erkan D, Boffa MC, Piette JC, et al. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-4.
10. Cervera R, Font J, Gómez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-9.
11. Asherson RA, Shoenfeld Y. The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome - Molecular mimicry? J Rheumatol. 2000;27:12-4.
12. Gharavi E, Cucurull E, Tang H, Celli CM, Wilson WA, Gharavi AE. Induction of antiphospholipid antibodies by immunization with viral peptides. Lupus 1999; 8: 449-455.
13. Gharavi AE, Pierangeli SS, Harris N. New developments in viral peptides and antiphospholipid antibody induction. J Autoimmunity. 2000;15:227-30.
14. Shoenfeld Y, Blank M, Cervera R, Font J, Raschi E, Meroni PL. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis. 2006;65:2-6.
15. Gómez-Puerta JA, Cervera R, Espinosa G, Aguiló S, Bucciarelli S, Ramos-Casals M, et al. Antiphospholipid antibodies associated with malignancies: Clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35:322-32.
16. Kitchens CS. Thrombotic storm: When thrombosis begets thrombosis. Am J Med. 1998;104:381-5.
17. Amital H, Levy Y, Davidson C, Lundberg I, Harju A, Kosach Y, et al. Catastrophic antiphospholipid syndrome: remission following leg amputation. Semin Arthritis Rheum. 2001;31:127-132.
18. Cervera R, Bucciarelli S, Espinosa G, Gómez-Puerta JA, Ramos-Casals M, Shoenfeld Y, Piette J-C, Asherson RA. Catastrophic antiphospholipid syndrome: Lessons from the CAPS Registry” A tribute to the late Josep Font. Ann NY Acad Sci. 2007;1108:448-56.
19. Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: Therapeutic developments. Expert Rev Clin Immunol. 2007;3:277-85 20. Espinosa G, Bucciarelli S, Cervera R,
ómez-Puerta JA, Font J. Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6:68-71.
21. Cervera R, Asherson RA, Font J. Catastrophic antiphospholipid syndrome. Rheum Dis Clin N Am. 2006;32: 575-90.
22. Bucciarelli S, Espinosa G, Asherson RA, Cervera R, Claver G, Gómez-Puerta JA, et al. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis
f a series of 47 patients. Ann Rheum Dis. 2006;65: 81-6.
23. Asherson RA, Espinosa G, Cervera R, Gómez-Puerta JA, Musuruana J, Bucciarelli S, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome:
linical and haematological characteristics of 23 patients. Ann Rheum Dis. 2005;64:943-6.
24. Espinosa G, Bucciarelli S, Cervera R, Lozano M, Reverter JC, De la Red G, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum is. 2004;63:730-6.
25. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification
riteria for definite antiphospholipid syndrome (APS). J Thromb Haemostas. 2006;4:295-306.
26. Bucciarelli S, Espinosa G, Cervera R, Erkan D, GómezPuerta JA, Ramos-Casals M, et al. For the CAPS Registry Project Group (European Forum on Antiphsopholipid Antibodies).
ortality in the catastrophic antiphospholipid syndrome. Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568-76.
Descargas
Los datos de descargas todavía no están disponibles.